Coronavirus Overview: Structure, Genome & Pathogenesis

The coronavirus is an enveloped, positive-sense single-stranded RNA (+ssRNA) virus that causes respiratory, enteric, hepatic, and neurologic disease in humans and animals.

Human coronaviruses (HCoVs) include four “common cold” viruses (229E, NL63, OC43, HKU1) and three highly pathogenic species causing severe lower respiratory tract disease: SARS-CoV, MERS-CoV, and SARS-CoV-2.

• Large RNA genomes (~26–32 kb) and high recombination rates drive rapid evolution, host-switching, and emergence of novel strains.
• SARS-CoV-2, a betacoronavirus first detected in 2019, caused the COVID-19 pandemic and dominates current coronavirus research.

Coronaviruses are now a central model for RNA virus biology, immune evasion, and pandemic emergence.

Taxonomy and Classification of Coronavirus

• Order: Nidovirales
• Family: Coronaviridae
• Subfamily: Orthocoronavirinae
• Genera:

-Alphacoronavirus: HCoV-229E, HCoV-NL63, and numerous bat and animal CoVs.

-Betacoronavirus: HCoV-OC43, HCoV-HKU1, SARS-CoV, MERS-CoV, SARS-CoV-2.

-Gammacoronavirus: mainly avian viruses (e.g., infectious bronchitis virus).

-Deltacoronavirus: swine and avian CoVs.

Key taxonomic points:

• At least 39 species in 27 subgenera are now recognized within Coronaviridae, with substantial host and sequence diversity.
• The three lethal human CoVs (SARS-CoV, MERS-CoV, SARS-CoV-2) are betacoronaviruses of zoonotic origin, all with ancestral links to bats and, in some cases, intermediate hosts (civets for SARS-CoV, dromedaries for MERS-CoV).
• Classification is based on phylogeny of the conserved replicase genes (ORF1a/ORF1b) and whole-genome analyses.

Structure and Morphology of Coronavirus

• Virion size and shape

-Roughly spherical or pleomorphic, 60–140 nm in diameter; SARS-CoV-2 particles ~80–120 nm.

-Surface densely coated with club-shaped spike (S) glycoproteins, giving a crown-like (“corona”) appearance by EM.

• Structural components:

-Spike (S):

• Class I fusion glycoprotein forms homotrimers.
• Responsible for receptor binding and membrane fusion; major target of neutralizing antibodies and vaccines.

-Membrane (M):

• Most abundant envelope protein; type III transmembrane glycoprotein.
• Organizes virion shape and coordinates assembly with N and E.

-Envelope (E):

• Small hydrophobic protein (~8–12 kDa).
• Functions in assembly, budding, and ion channel activity; contributes to virulence and inflammatory responses.

-Nucleocapsid (N):

• Phosphoprotein that binds genomic RNA to form a helical ribonucleoprotein.
• Involved in genome packaging, replication, and modulation of host responses.

-Some betacoronaviruses (e.g., HCoV-OC43, HKU1) additionally encode hemagglutinin-esterase (HE), aiding attachment and receptor destruction.

• Envelope origin and budding site

-Envelope and spikes are derived from host ER–Golgi intermediate compartment (ERGIC) membranes during intracellular budding.

Genome Organization and Proteins of Coronavirus

• Genome features

-Non-segmented, +ssRNA, 26–32 kb – the largest known RNA virus genomes.

-5′ capped and 3′ polyadenylated, similar to host mRNA.

-Canonical organization:

• 5′-leader-UTR-ORF1a/ORF1b (replicase)-S-E-M-N-3′UTR-poly(A) with accessory genes interspersed among structural genes.
• Replicase polyproteins and non-structural proteins (nsps)

-ORF1a and ORF1b occupy ~2/3 of the genome and encode polyproteins pp1a and pp1ab.

-pp1ab produced via a −1 ribosomal frameshift at the ORF1a/1b overlap.

-Polyproteins are cleaved by:

• Papain-like protease (PLpro; nsp3)
• 3C-like main protease (3CLpro or Mpro; nsp5)
  into 16 nsps (nsp1–16) in most CoVs.
• Major nsp functions:

-nsp1: host mRNA degradation, translation shutoff (immune evasion).

-nsp3 (PLpro): protease, deubiquitinase, deISGylase (antagonizes innate signaling).

-nsp5 (Mpro): main protease – key antiviral drug target.

-nsp7/8: primase/cofactor complexes.

-nsp12: RNA-dependent RNA polymerase (RdRp) – target of remdesivir and other nucleoside analogs.

-nsp13: helicase with NTPase activity.

-nsp14: 3′–5′ exonuclease (ExoN) providing proofreading, enabling the unusually large genome; also N7-methyltransferase.

-nsp15 (NendoU), nsp16 (2′-O-methyltransferase): RNA processing and cap modification, aiding immune evasion.

• Structural and accessory genes

-Downstream one-third of the genome encodes S, E, M, N, and multiple accessory proteins (e.g., ORF3a, ORF6, ORF7a, ORF8 in SARS-CoV-2) that modulate host responses and virulence.

-Accessory genes are dispensable for replication in vitro but important for pathogenicity and host range.

Table 1: The 16 nonstructural proteins of coronaviruses and their functions (https://doi.org/10.1002/jmv.25681)

Replication Cycle of Coronavirus

• Attachment and entry:

-S protein binds host receptors, which differ among CoVs:

• SARS-CoV and SARS-CoV-2: ACE2
• MERS-CoV: DPP4 (CD26)
• HCoV-229E: APN (CD13); HCoV-OC43/HKU1: sialic acids.

-Attachment factors (heparan sulfate, lectins) can enhance binding.

-Proteolytic activation of S by host proteases (TMPRSS2, furin, cathepsins) triggers:

• Direct plasma membrane fusion or
• Endocytosis and fusion in endosomes.
• Translation of replicase and formation of RTC

-Incoming genomic RNA serves as mRNA for ORF1a/1b.

-Translation produces pp1a/pp1ab → processed into nsps that assemble into the replication–transcription complex (RTC) on remodeled intracellular membranes.

• Replication organelles

-CoVs extensively remodel ER membranes to form:

• Double-membrane vesicles (DMVs)
• Convoluted membranes and double-membrane spherules.

-These structures concentrate viral proteins and shield dsRNA intermediates from innate sensors.

• RNA synthesis

-RTC performs:

• Genome replication: full-length negative-strand template → new genomic +RNA.
• Discontinuous transcription: synthesis of a nested set of subgenomic negative RNAs, which serve as templates for subgenomic mRNAs encoding structural/accessory proteins.
• Assembly and release

-Structural proteins S, E, and M are synthesized on rough ER and localize to ERGIC/Golgi.

-N-genomic RNA complexes bud into ERGIC membranes containing M, E, and S → formation of virions.

-Virions are transported in vesicles and released by exocytosis. Some CoVs also show lysosomal egress and cell-to-cell spread.

Pathogenesis and Host Immune Response to Coronavirus

The pathogenesis of SARS-CoV is characterized by its ability to infect ciliated airway epithelial cells and alveolar Type II pneumocytes using the ACE2 receptor. In severe cases, the disease progresses to acute respiratory distress syndrome (ARDS), involving pulmonary edema, hypoxia, and a hyper-accumulation of inflammatory cells. This progression is often driven by aberrant and persistent cytokine and chemokine responses, leading to systemic inflammation and multiple organ failure.

Host Immune Response

The host’s defense relies primarily on innate immune signaling triggered by Pattern Recognition Receptors (PRRs):

• Detection: Cytosolic sensors like RIG-I and MDA5 and membrane-bound Toll-Like Receptors (TLRs) recognize viral components, initiating signaling cascades.
• Signaling Pathways: These sensors activate transcription factors such as IRF3 and IRF7, which induce Type I Interferons (IFNs), and NF-κB, which triggers proinflammatory cytokines.
• Protective Factors: Proteins like STAT1 and MyD88 are crucial for survival; for instance, STAT1 is essential for resolving the primary infection and regulating the antiviral state.
• Delayed Response: In severe SARS disease, the Interferon response is often delayed (detected at 48 hours post-infection compared to 12 hours for proinflammatory cytokines), which may prevent the host from effectively controlling early viral replication.

Viral Evasion and Antagonism

SARS-CoV has evolved complex mechanisms to evade and antagonize the immune system:

• Interferon Antagonism: The virus encodes at least eight proteins (including nsp1, ORF6, and the N and M proteins) that actively block the production or signaling of IFNs. For example, ORF6 prevents the nuclear import of STAT1, effectively “blunting” the antiviral response.
• Evasion of Detection: The virus uses proteins like nsp14 and nsp16 to “cap” its RNA, making it look like host mRNA to avoid being detected by sensors like MDA5.
• Host Shutoff: The protein nsp1 promotes the degradation of host mRNA and inhibits host translation, while viral RNA remains resistant to this cleavage.

Pathogenesis

• Cellular and tissue tropism

-Major target: respiratory epithelium, particularly type II alveolar cells expressing ACE2 or DPP4.

-Systemic dissemination can involve the endothelium, heart, kidney, gut, CNS, and immune cells, leading to multi-organ involvement in severe COVID-19.

• Innate immune recognition and evasion:

-PAMPs: viral RNA sensed by RIG-I, MDA5, TLR3, TLR7/8, activating type I/III IFN and NF-κB pathways.

-Pathogenic CoVs actively suppress or delay IFN responses through multiple proteins (nsp1, PLpro/nsp3, nsp14, ORF3b, ORF6, etc.).

-Dysregulated innate responses can result in hyper-inflammation and cytokine storm (elevated IL-6, IL-1β, TNF-α, chemokines), central to severe COVID-19 and SARS.

• Adaptive immunity

-Neutralizing antibodies target S, especially the receptor-binding domain, and N; protective but can wane over months.

-CD4⁺ and CD8⁺ T cells recognize epitopes from S, M, N, and non-structural proteins; robust T-cell responses correlate with viral clearance and milder disease, whereas lymphopenia and exhausted phenotypes (PD-1⁺, TIM-3⁺) associate with severe disease.

• Immunopathology

-In severe SARS and COVID-19, lung pathology shows diffuse alveolar damage, hyaline membranes, edema, microthrombi, and extensive inflammatory infiltrates, reflecting both direct cytopathic effects and immune-mediated injury.

-Endothelial infection, complement activation, and NETs contribute to a pro-thrombotic state and multi-organ damage in COVID-19.

Table 2: List of important pathogenic coronaviruses (https://doi.org/10.1002/jmv.25681)

Epidemiology and Transmission of Coronavirus

• Human CoVs

-Endemic HCoVs (229E, NL63, OC43, HKU1):

• Cause 5–30% of common colds worldwide; predominantly upper respiratory infections.

-SARS-CoV (2002–2004):

• ~8,000 cases, CFR ~10%; outbreak controlled by isolation and contact tracing.

-MERS-CoV (since 2012):

• ~35% CFR, mainly in the Middle East; zoonotic transmission from dromedaries plus limited human-to-human spread.

-SARS-CoV-2 (since 2019):

• Global pandemic; basic R₀ initially estimated ~2–3, modulated by variants and interventions.
• Transmission modes (SARS-CoV-2):

-Respiratory droplets and aerosols during close contact.

Fomite transmission via contaminated surfaces (probably secondary).

-Highest infectiousness around symptom onset; substantial presymptomatic and asymptomatic transmission.

• Reservoirs and zoonotic origin

-Most CoVs have primary reservoirs in bats and birds, with occasional spillover via intermediate hosts (civets, camels, possibly other mammals).

Clinical Manifestations of Coronavirus

Overall Clinical Spectrum and Severity

COVID-19 ranges from asymptomatic or mildly symptomatic cases to severe and critical disease. Many patients, especially children and younger adults, remain asymptomatic or display only mild upper-respiratory or systemic symptoms. Symptomatic disease classically begins with fever, dry cough, fatigue, and myalgia, sometimes accompanied by sore throat or nasal congestion. In moderate to severe cases, symptoms progress to dyspnea and radiologic evidence of viral pneumonia, while critically ill patients may develop acute respiratory distress syndrome (ARDS), respiratory failure, septic shock, and multi-organ dysfunction. Older age and comorbidities such as cardiovascular disease, diabetes, and chronic lung disease markedly increase the risk of severe outcomes.

Respiratory and Systemic Features

The respiratory system is most commonly affected. Core manifestations include fever, cough (usually dry), shortness of breath, sore throat, and sometimes sputum production or chest pain. Pneumonia is the predominant complication, often characterized by bilateral, peripheral ground-glass opacities and consolidation on chest CT. Systemically, patients frequently report fatigue, myalgia, headache, and chills, with laboratory findings of lymphopenia, elevated inflammatory markers (CRP, ESR), and coagulation abnormalities such as increased D-dimer. These abnormalities correlate with disease severity and adverse prognosis.

Neurological, Olfactory, and Gustatory Manifestations

Neurological involvement is common: over one-third of hospitalized patients have neurologic symptoms, which are more frequent in severe disease. Non-specific complaints include headache, dizziness, confusion, delirium, and myalgia, while serious manifestations comprise encephalopathy, stroke, seizures, meningoencephalitis, Guillain–Barré syndrome, acute myelitis, and posterior reversible encephalopathy syndrome. Highly characteristic are olfactory and gustatory dysfunctions (anosmia, hyposmia, ageusia), which may appear early or even as isolated symptoms. Many of these neurological features likely reflect a combination of direct viral neurotropism, endothelial injury, immune-mediated mechanisms, and systemic inflammation.

Gastrointestinal, Hepatic, and Other Extrapulmonary Features

Gastrointestinal symptoms—notably diarrhea, nausea, vomiting, abdominal pain, and anorexia—occur in a substantial proportion of patients and may precede respiratory complaints. Hepatic involvement is reflected by elevations in AST, ALT, and bilirubin, often associated with more severe disease. The cardiovascular system can show chest pain, palpitations, arrhythmias, myocarditis, and acute cardiac injury, frequently linked to increased mortality. Renal manifestations include proteinuria, hematuria, and acute kidney injury, especially in critically ill patients. Dermatologic findings range from chilblain-like (pernio) lesions to maculopapular, vesicular, urticarial, livedoid, and necrotic rashes. Ocular symptoms, particularly conjunctivitis, and various endocrine disturbances (worsening hyperglycemia, ketoacidosis, sex-hormone changes) are also reported.

Pediatric and Long-Term Manifestations

In children, infections are often asymptomatic, mild, or moderate, with fever, cough, and nasal symptoms most common, while severe pneumonia is relatively rare. However, a post-infectious multisystem inflammatory syndrome in children (MIS-C) presents with persistent fever, mucocutaneous signs, gastrointestinal symptoms, and cardiovascular dysfunction, frequently requiring intensive care. Beyond the acute phase, many patients experience “long-COVID”, a multi-organ syndrome featuring persistent fatigue, “brain fog,” headache, cognitive impairment, dyspnea, sleep and mood disorders, myalgias, and dysautonomia, sometimes lasting months after initial infection. These prolonged manifestations underscore that COVID-19 is best understood as a multisystem disease with diverse and evolving clinical presentations.

Laboratory Diagnosis of Coronavirus

• Nucleic acid amplification tests (NAATs)

-RT-PCR is the diagnostic gold standard for SARS-CoV-2.

• Targets: E, RdRp, N, ORF1ab genes.
• Respiratory specimens: naso-/oropharyngeal swabs, lower respiratory samples in severe disease.

-Multiplex panels can simultaneously detect common HCoVs and other respiratory viruses.

• Antigen tests

-Rapid immunochromatographic assays detecting N protein in respiratory samples.

-Lower sensitivity than RT-PCR but useful for point-of-care, high-throughput screening.

• Serology

-ELISA, CLIA detecting IgM, IgG, and IgA against S and N.

-Useful for:

• Past infection and seroprevalence.
• Supporting diagnosis in late or post-acute phases.

-Not reliable for early acute diagnosis due to seroconversion delay (typically ≥7–14 days).

• Other laboratory markers (prognosis):

Elevated D-dimer, ferritin, IL-6, troponin, and lymphopenia correlate with worse outcomes.

Treatment and Antiviral Therapy of Coronavirus

Therapeutic strategies focus on (1) direct antivirals, (2) immunomodulation, and (3) supportive care.

• Direct-acting antivirals (SARS-CoV-2):

-Remdesivir: nucleoside analog targeting RdRp (nsp12); shortens recovery time in hospitalized patients requiring oxygen but with limited mortality benefit.

-Nirmatrelvir/ritonavir (Paxlovid): oral Mpro inhibitor plus pharmacokinetic booster; effective in reducing hospitalization and death in high-risk outpatients.

-Other candidates/trials: favipiravir, molnupiravir, and host-targeted agents (e.g., TMPRSS2 inhibitors).

• Immunomodulatory therapy:

-Dexamethasone and other systemic corticosteroids:

• Reduce mortality in patients requiring oxygen or mechanical ventilation by dampening hyper-inflammation.

-IL-6 receptor antagonists (tocilizumab, sarilumab):

• Benefit in selected severe/critical cases with high inflammatory markers.

-JAK inhibitors (e.g., baricitinib) and other cytokine blockers under evaluation.

• Passive immunotherapy

-Monoclonal antibodies targeting S (e.g., REGN-COV, others), especially for early disease or prophylaxis in high-risk individuals; efficacy varies with viral variants.

-Convalescent plasma: mixed evidence; may offer benefit only when given early and with high neutralizing titers.

• Supportive and adjunctive care

-Oxygen therapy, mechanical ventilation, anticoagulation for thromboembolic risk, and management of organ failure.

• Vaccines (prevention-linked but central to therapy landscape)

-mRNA vaccines (BNT162b2, mRNA-1273), adenoviral vectors, and inactivated and protein-subunit vaccines demonstrate high efficacy in preventing severe COVID-19, though reduced against some variants.

Prevention and Control of Coronavirus

• Non-pharmaceutical interventions (NPIs):

-Masking, physical distancing, ventilation, and hand hygiene.

-Isolation of cases, contact tracing, quarantine.

-Travel restrictions and public-health surveillance.

• Vaccination

-Primary tool for controlling SARS-CoV-2 spread and reducing morbidity and mortality.

-Booster doses necessary to counter waning immunity and variant escape.

• Infection prevention in healthcare settings

-Standard, contact, and airborne precautions for aerosol-generating procedures.

-PPE use, environmental cleaning, and cohorting of COVID-19 patients.

• Zoonotic and environmental control

-Monitoring of animal reservoirs (bats, camels, minks, others), wildlife trade, and farming practices to reduce spillover risk.

-Strengthening global genomic surveillance to detect emerging variants and novel coronaviruses.

Conclusion

Coronaviruses are +ssRNA viruses with large genomes and complex replication-transcription machineries. They have an extensive ability to expand their host range and evade the immune system. Among the seven human CoVs, three betacoronaviruses, SARS CoV, MERS CoV, and SARS-CoV-2, are responsible for severe lower respiratory tract diseases, systemic complications, and organ failure. SARS CoV-2 causes an unprecedented global pandemic.

The pathogenesis of these three betacoronaviruses includes tropism for respiratory and extrapulmonary tissues, delayed or absent interferon production, intense but disorganized inflammatory reactions, and immunopathology induced by the virus. Advances in molecular virology have revealed many targets for antiviral drugs (Mpro, PLpro, RdRp, entry factors) and have enabled the rapid development of effective vaccines and drugs.

References

1. V’kovski, P., Kratzel, A., Steiner, S., Stalder, H., & Thiel, V. (2021). Coronavirus biology and replication: Implications for SARS-CoV-2. Nature Reviews Microbiology, 19(3), 155–170. https://doi.org/10.1038/s41579-020-00468-6
2. Hartenian, E., Nandakumar, D., Lari, A., Ly, M., Tucker, J. M., & Glaunsinger, B. A. (2020). The molecular virology of coronaviruses. Journal of Biological Chemistry, 295(37), 12910–12934. https://doi.org/10.1074/jbc.REV120.013930
3. Tu, Y. F., Chien, C. S., Yarmishyn, A. A., Lin, Y. Y., Luo, Y. H., Lin, Y. T., … Chiou, S. H. (2020). A review of SARS-CoV-2 and the ongoing clinical trials. International Journal of Molecular Sciences, 21(7), 2657. https://doi.org/10.3390/ijms21072657
4. Chilamakuri, R., & Agarwal, S. (2021). COVID-19: Characteristics and therapeutics. Cells, 10(2), 206. https://doi.org/10.3390/cells10020206
5. Kaul, D. (2020). An overview of coronaviruses, including the SARS-2 coronavirus – Molecular biology, epidemiology, and clinical implications. Current Medicine Research and Practice, 10(2), 54–64. https://doi.org/10.1016/j.cmrp.2020.04.001
6. Kirtipal, N., Bharadwaj, S., & Kang, S. (2020). From SARS to SARS-CoV-2, insights on structure, pathogenicity, and immunity aspects of pandemic human coronaviruses. Infection, Genetics and Evolution, 85, 104502. https://doi.org/10.1016/j.meegid.2020.104502
7. Chen, B., Tian, E. K., He, B., Tian, L., Han, R., Wang, S., … Cheng, W. (2020). Overview of lethal human coronaviruses. Signal Transduction and Targeted Therapy, 5, 89. https://doi.org/10.1038/s41392-020-0190-2
8. Chen, Y., Liu, Q., & Guo, D. (2020). Emerging coronaviruses: Genome structure, replication, and pathogenesis. Journal of Medical Virology, 92(4), 418–423. https://doi.org/10.1002/jmv.25681
9. Kheirandish Zarandi, P., Zinatizadeh, M. R., Zinatizadeh, M., Yousefi, M. M., Rezaei, N., & others. (2021). SARS-CoV-2: From the pathogenesis to potential anti-viral treatments. Biomedicine & Pharmacotherapy, 137, 111268. https://doi.org/10.1016/j.biopha.2021.111268
10. Raoult, D., Zumla, A., Locatelli, F., Ippolito, G., & Kroemer, G. (2020). Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses. Cell Stress, 4(4), 66–75. https://doi.org/10.15698/cst2020.04.216
11. Triggle, C. R., Bansal, D., Ding, H., Islam, M. M., Farag, E. A., Hadi, H. A., & Sultan, A. A. (2021). A comprehensive review of viral characteristics, transmission, pathophysiology, immune response, and management of SARS-CoV-2 and COVID-19 as a basis for controlling the pandemic. Frontiers in Immunology, 12, 631139. https://doi.org/10.3389/fimmu.2021.631139
12. Hassan, S. A., Sheikh, F. N., Jamal, S., Ezeh, J. K., & Akhtar, A. (2020). Coronavirus (COVID-19): A review of clinical features, diagnosis, and treatment. Cureus, 12(3), e7355. https://doi.org/10.7759/cureus.7355
13. Xie, M., & Chen, Q. (2020). Insight into 2019 novel coronavirus — An updated interim review and lessons from SARS-CoV and MERS-CoV. International Journal of Infectious Diseases, 94, 119–124. https://doi.org/10.1016/j.ijid.2020.03.071
14. Machhi, J., Herskovitz, J., Senan, A. M., Dutta, D., Nath, B., Oleynikov, M. D., … Kevadiya, B. D. (2020). The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections. Journal of Neuroimmune Pharmacology, 15(3), 359–386. https://doi.org/10.1007/s11481-020-09944-5
15. Li, X., Geng, M., Peng, Y., Meng, L., & Lu, S. (2020). Molecular immune pathogenesis and diagnosis of COVID-19. Journal of Pharmaceutical Analysis, 10(2), 102–108. https://doi.org/10.1016/j.jpha.2020.03.001
16. Ortiz Prado, E., Simbaña Rivera, K., Gómez Barreno, L., Rubio Neira, M., Guaman, L. P., Kyriakidis, N. C., … López Cortés, A. (2020). Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19): A comprehensive literature review. Diagnostic Microbiology and Infectious Disease, 98(1), 115094. https://doi.org/10.1016/j.diagmicrobio.2020.115094
17. Sofi, M. S., Hamid, A., & Bhat, S. U. (2020). Coronavirus COVID-19: A critical review of its history, pathogenesis, transmission, diagnosis, and treatment. Biosafety and Health, 2(4), 217–225. https://doi.org/10.1016/j.bsheal.2020.10.002
18. Totura, A. L., & Baric, R. S. (2012). SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon. Current Opinion in Virology, 2(3), 264–275. https://doi.org/10.1016/j.coviro.2012.04.004
19. Zhou, Z., Qiu, Y., & Ge, X. (2021). The taxonomy, host range, and pathogenicity of coronaviruses and other viruses in the Nidovirales order. Animal Diseases, 1, 5. https://doi.org/10.1186/s44149-021-00005-9
20. Rabaan, A. A., Al-Ahmed, S. H., Sah, R., Tiwari, R., Yatoo, M. I., Patel, S. K., … Leblebicioglu, H. (2020). SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic. Annals of Clinical Microbiology and Antimicrobials, 19, 40. https://doi.org/10.1186/s12941-020-00384-w
21. Malik, Y. S. (2020). Properties of coronavirus and SARS-CoV-2. Malaysian Journal of Pathology, 42(1), 3–11.
22. Artika, I. M., Dewantari, A. K., & Wiyatno, A. (2020). Molecular biology of coronaviruses: current knowledge. Heliyon, 6(8), e04743. https://doi.org/10.1016/j.heliyon.2020.e04743
23. Barupal T, Tak PK, Meena M. COVID-19: Morphology, Characteristics, Symptoms, Prevention, Clinical Diagnosis and Current Scenario. Res Rev Biosci. 2020;15(2):153.
24. V’kovski, P., Kratzel, A., Steiner, S., Stalder, H., & Thiel, V. (2020). Coronavirus biology and replication: implications for SARS-CoV-2. Nature Reviews Microbiology, 19(3), 155–170. https://doi.org/10.1038/s41579-020-00468-6